MARKET OUTLOOK
The hospital-treated gram-negative infection (GNI) therapy market is dominated by highly effective, generically available antibiotics. However, the rising prevalence of multidrug-resistant (MDR) pathogens makes GNIs increasingly challenging to treat. Potent antibiotics such as carbapenems are losing efficacy, driving the use of older antibiotics with toxic side effects. New antibiotics—Merck’s Zerbaxa, Allergan’s Avycaz, and Melinta’s Vabomere—retain activity against MDRgram-negative pathogens and thus provide a therapeutic alternative, but there are challenges to their use (e.g., price). In addition, the pipeline of new agents that can address the threat of MDR bacteria is populated with candidates from multiple classes. As payers, hospitals, and prescribers balance clinical need with budget constraints, the value proposition for new drugs must be tailored to secure optimal market share in what is fast becoming a crowded segment of the GNItherapymarket.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
Access & Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so that clients can build their market access strategy and optimize their brand positioning.
Geography
Survey of 142 U.S. ID specialists and 31 U.S. hospital pharmacy directors (PDs).
Key drugs covered
Avycaz, Zerbaxa, Vabomere, Invanz, Minocin, Teflaro, and other key generic GNI drugs
Content highlights